個案總覽
依發行單位、學門或關鍵字，找到適合的教學個案。
-
NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK
NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient 10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.